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ABSTRACT
Due to their mode of action, ribozymes show anti-
sense effects in addition to their specific cleavage
activity. In the present study we investigated whether
a hammerhead ribozyme is capable of cleaving
mutated Ki-ras mRNA in a pancreatic carcinoma cell
line and whether antisense effects contribute to the
activity of the ribozyme. A 2'-O-allyl modified hammer-
head ribozyme was designed to cleave specifically
the mutated form of the Ki-ras mRNA (GUU motif in
codon 12). The activity was monitored by RT–PCR on
Ki-ras RNA expression by determination of the relative
amount of wild type to mutant Ki-ras mRNA, by 5-
bromo-2'-deoxy-uridine incorporation on cell prolifer-
ation and by colony formation in soft agar on malig-
nancy in the human pancreatic adenocarcinoma cell
line CFPAC-1, which is heterozygous for the Ki-ras
mutation. A catalytically inactive ribozyme was used
as control to differentiate between antisense and
cleavage activity and a ribozyme with random guide
sequences as negative control. The catalytically
active anti-Ki-ras ribozyme was at least 2-fold more
potent in decreasing cellular Ki-ras mRNA levels,
inhibiting cell proliferation and colony formation in
soft agar than the catalytically inactive ribozyme. The
catalytically active anti-Ki-ras ribozyme, but not the
catalytically inactive or random ribozyme, increased
the ratio of wild type to mutated Ki-ras mRNA in
CFPAC-1 cells. In conclusion, both cleavage activity
and antisense effects contribute to the activity of the
catalytically active anti-Ki-ras hammerhead ribozyme.
Specific ribozymes might be useful in the treatment
of pancreatic carcinomas containing an oncogenic
GTT mutation in codon 12 of the Ki-ras gene.
INTRODUCTION
Antisense oligonucleotides and ribozymes are powerful tools
for the specific suppression of gene expression. In contrast to
antisense oligonucleotides, ribozymes possess an additional
catalytic activity to cleave RNA without the help of an enzyme
(1). In most applications the hammerhead-type ribozyme is
used. It consists of a catalytic loop and three stems, two of
which contain the sequence complementary to the target
sequence (2). Hammerhead ribozymes were first recognized as
a sequence motif responsible for self-cleavage of satellite
RNAs of certain viruses (3). They can cleave complementary
substrate RNAs in cis and trans (4). Cleavage occurs through
transesterification which produces RNA with terminal 5'-
hydroxyl and 2',3'-cyclic phosphate groups. An important
requirement for hammerhead ribozyme-mediated target cleav-
age is the presence of an NUX-base triplet in the target RNA
sequence (N corresponds to any ribonucleotide and X corres-
ponds to A, C and U) adjacent to the 3' cleavage site (5).
The three members of the ras gene family (Ha-ras,K i - ras
and N-ras) have been identified as active oncogenes in many
different human tumors (6,7). About 90% of human pancreatic
carcinomas possess a point mutation in codon 12 of the Ki-ras
gene, leading to continuous proliferation and transformation
by the expression of p21 Ras oncoprotein. Approximately 30%
of these Ki-ras mutations are G to T transversions in the second
position of codon 12. Inhibition of mutated ras expression by
ribozymes has been shown to suppress the malignant pheno-
type of Ha-ras transformed NIH 3T3 cells (8). To investigate if
ananti-Ki-ras ribozymecouldbeusedinthetreatmentofpancreatic
cancer, we studiedthe effects of a 2'-O-allyl modifiedhammer-
headribozymeonKi-rasmRNAexpressionandcellproliferation.
The ribozyme was designed to cleave specifically the mutated
form of the Ki-ras mRNA with the GUU motif at codon 12.
The human pancreatic adenocarcinoma cell line CFPAC-1 is
heterozygous for Ki-ras and expresses both the wild type
(GGU) and the mutated mRNA with the GUU motif at codon 12.
This cell line is therefore an excellent model to differentiate




FCS, Iscove’s modified Dulbecco’s medium, Lipofectin, penicillin,
streptomycin, fungizone and reverse transcriptase (Superscript)
were obtained from Life Technologies, Inc. (Eggenstein,
Germany). The 5-bromo-2'-deoxy-uridine (BrdU) Labeling
and Detection Kit III, DOTAP, Taq DNA polymerase and
RNase inhibitor werefromBoehringer Mannheim(Mannheim,
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Germany). The pGEM-T vector PCR cloning system was from
Promega (Madison, WI). The Dye Deoxy Terminator Kit was
from Applied Biosystems (Weiterstadt, Germany).
Ribozyme synthesis and sequence characteristics
The hammerhead ribozyme, the catalytically inactive ribozyme
and a random ribozyme were chemically synthesized (Tib
Molbiol, Berlin, Germany). The hammerhead ribozyme and
the catalytically inactive ribozyme contain binding arms (8 and
9 nt) to anneal to the Ki-ras mRNA and an invariant core
sequence (22 nt) required for catalytic activity. The anti-Ki-ras
hammerhead ribozyme (5'-ccuacgcccuGAuGAggccgugag-
gccGAAAcagcucca-3') was designed to cleave specifically the
mutated form of the Ki-ras mRNA with the GUU motif at
codon 12. Lowercase letters indicate 2'-O-allyl modifications
and uppercase characters indicate unmodified ribonucleotides.
The catalytically inactive ribozyme (5'-ccuacgcccugAuGAg-
gccgugaggccGAAAcagcucca-3') had the same sequence and
modifications as the catalytically active ribozyme except for a
2'-O-allyl modification in position 5 (bold letter), according to
the numbering system for hammerhead ribozymes (9). The
random ribozyme (5'-accccuuacuGAuGAggccgugaggccGAAG-
uccgaccc-3') contained the core sequence of the hammerhead
ribozyme, but the binding arms were randomly chosen
sequences. All backbone linkages are normal phosphodiesters.
Cell culture
The human pancreatic carcinoma cell line CFPAC-1 (Euro-
pean Collection of Animal Cell Cultures, Salisbury, UK) was
used (10). Cells express the wild type and the mutated form of
the Ki-ras mRNA with a GGU and GUU motif at codon 12,
respectively. The cells were grown in Iscove’s modified
Dulbecco’s medium supplemented with 10% FCS and anti-
biotics (100 U/ml penicillin, 100 mg/ml streptomycin and
0.25 mg/ml fungizone). All incubations were carried out at
37°C, 5% CO2, in humidified atmosphere.
In vitro cleavage assay
Two target RNAs of 281 nt in length were synthesized by T7
polymerase transcription from Ki-ras cDNA templates. The
RNAs represent the coding region (nucleotide position 1–257)
of the Ki-ras mRNA with the GGU and GUU motif at codon
12, respectively. Fifty picomoles of the hammerhead ribozyme,
catalytically inactive ribozyme or random ribozyme were
mixed with 10 pmol of the respective target RNA in a total
volume of 10 ml containing 100 mM Tris–HCl, pH 7.5, and
2 mM EDTA. The mixture was heated to 95°C for 10 min and
subsequently chilled on ice. The cleavage was started by adding
MgCl2 to a final concentration of 10 mM in a reaction volume
of 20 ml followed by an incubation at 37°C. Aliquots at time
points 0, 2, 4, 16 and 24 h were mixed with formamide, heat
denatured at 95°C for 10 min and visualized by denaturing 6%
polyacrylamide–urea gel electrophoresis and silver staining.
The intensity of the bands was determined densitometrically.
Stability of the ribozymes in cell culture
Hammerhead ribozyme, catalytically inactive ribozyme or
random ribozyme (2 mM each) were incubated in a 6-well plate
with and without 105 C F P A C - 1c e l l sf o r0 ,1 ,2 ,3 ,4 ,5 ,6a n d
7 days. Aliquots of the supernatant collected at each time point
were mixed with formamide, heat denatured at 95°Cf o r
10 min, analyzed by denaturing 12% polyacrylamide–urea gel
electrophoresis and visualized by silver staining.
RT–PCR and amplicon analysis
Total RNA was isolated by the acid guanidinium isothiocyanate–
phenol–chloroform method from 105 CFPAC-1 cells which
had been incubated for 48 h with 0.05, 0.5, 1, 2 and 5 mMh a m m e r -
head ribozyme, catalytically inactive ribozyme, random
ribozyme, or without oligoribonucleotides. Total RNA
(0.5 mg) was denatured in the presence of 50 pmol oligo-d(T)16
primer at 70°C for 10 min and then chilled on ice. First strand
b u f f e r( 5 0m MT r i s – H C l ,p H8 . 3 ,7 5m MK C l ,3m MM g C l 2),
0.4 mM deoxynucleotide mix, 10 mM DTT, 20 U RNase
inhibitor and 200 U Superscript were added to a final volume
of 23 ml. The mixture was incubated at 37°C for 45 min. The
first strand cDNA was divided into two aliquots and used for
two separate PCRs. One PCR was performed with the sense
primer (5'-ATGACTGAATATAAACTTGTGGTA-3'), that
anneals to position 1–24 of the Ki-ras cDNA coding region
and the antisense primer (5'-TGTCTTGTCTTTGCTGAT-
GTTTCA-3'), that anneals to position 426–449 of the Ki-ras
cDNA coding region. This primer set generated a 449 bp RT–PCR
product which was designed to detect Ki-ras mRNA including
the ribozyme binding region. This amplicon is called the ‘long’
amplicon. The other RT–PCR generated a product of 338 bp
and was designed to detect Ki-ras mRNA excluding the
ribozyme binding site. The primer set consisted of the sense-112
(5'-GATTCCTACAGGAAGCAAGTAGTA-3') annealing to
position 112–135 of the Ki-ras cDNA coding region) and the
antisense primer (5'-TGTCTTGTCTTTGCTGATGTTTCA-3').
This amplicon is called the ‘short’ amplicon. Specific cleavage
of the mutated Ki-ras mRNA by the catalytically active
ribozyme should preclude RT–PCR amplification from pos-
ition 1 to 449 (‘long’ amplicon), but not from position 112 to
449 (‘short’ amplicon). Due to the loss of the cap-structure,
however, the cleaved Ki-ras mRNA will rapidly be degraded.
Thus, ribozyme-mediated cleavage of the Ki-ras mRNA will
specifically and primarily affect the amplification of the ‘long’
Ki-ras RT–PCR product, but indirectly and to a lesser extent
also the amplification of the ‘short’ Ki-ras RT–PCR product.
The PCR mix contained 11 ml of the RT reaction mixture,
21 ml water, 5 ml1 0 ´ PCR-buffer (100 mM Tris–HCl, pH 8.3,
500 mM KCl), 1.6 mM MgCl2, 5 pmol sense or sense-112
primer, 5 pmol antisense primer and 1 U Taq DNA polymerase
in a final volume of 50 ml. PCR was run for 40 cycles (30 s at
95°C, 30 s at 55°Ca n d3 0sa t7 2 °C). The RT–PCR products
were visualized on a 3%agarose gelstainedby ethidium bromide.
The intensity of the bands was determined densitometrically. The
Ki-ras RT–PCR achieved a sensitivity of 100 RNA molecules.
To disclose unspecific effects of the ribozymes, an actin-
specific RT–PCR was performed. The sequences of the actin
primers were: actin-sense (5'-GCCGCGCTCGTCGTCGACA-
ACGGC-3') and actin-antisense (5'-TTCTCCATGTCGTCC-
CAGTTGGTG-3'). All other experimental conditions were
identical to those for amplification of Ki-ras.T h eR T – P C R
amplification of the ‘short’ and ‘long’ amplicon of Ki-ras
mRNA was investigated in the absence and presence of
increasingamounts ofcatalyticallyactive, catalyticallyinactive or
random ribozyme. Neither ribozyme inhibited the RT–PCR at
concentrations applied in the cell culture assays, excluding
unspecific inhibition of the RT–PCR.Nucleic Acids Research, 1999, Vol. 27, No. 13 2739
To determine the relative amount of wild type to mutant
RNA, the 449-bp ampliconswere cloned andsequenced before
and after treatment of CFPAC-1 cells with the ribozymes
(pGEM-T Kit, according to the manufacturer’s instructions).
Sequencing was performed by an automat (Applied Bio-
systems 373 A DNA Sequencer, Weiterstadt, Germany) using
the PCR-primers for the ‘long’ amplicon according to the
instructions of the Dye Deoxy Terminator protocol.
Cell proliferation assay
Cells were seeded in 96-well plates (1000 cells per well) in
100 ml complete cell culture medium. After preincubation for
3 days, the medium was replaced and the cells were incubated
for 24 and 48 h with hammerhead ribozyme, catalytically
inactive ribozyme, random ribozyme, or without oligoribo-
nucleotides in quadruplicate, respectively. The proliferation
assay was performed with the BrdU Labeling and Detection
Kit III according to the manufacturer’s manual. 5-bromo-2'-
deoxyuridine was added and after 3 h the optical density of the
incorporated dye was measured at 405 nm.
Cationic lipid-mediated uptake of the ribozymes
To investigate the benefit of cationic lipid mediated uptake of
the ribozymes, CFPAC-1 cells were incubated with 0.88 mg
DOTAP and 0.88 mg (corresponding to 0.5 mM) of the
ribozymes or genomic, ultrasonic fragmentated DNA as a control
for 24 or 48 h, respectively. According to the instructions of
the manufacturer, we have incubated the cells with DOTAP for
3 h without FCS and added serum only for the remaining
incubation period. The DOTAP concentration was chosen
according to previous studies (11). In addition, we complexed
ribozymes with DOTAP in ratios of 4:1 to 1:4. We found that
a ratio above 1:1 was toxic to the cells, while the effects of the
anti-Ki-rasribozymeson cell proliferation were not influenced
by the addition of DOTAP in ratios from 4:1 to 1:1.
Colony formation in soft agar
Untreated cells, cells treated with 2 mM catalytically active,
catalytically inactive or random ribozyme were seeded in
duplicate in 24-well plates (1000 cells per well) in 0.33% soft
agar and layered on top of a 0.5% soft agar base layer with
complete cell culture medium. After the first and second week,
200 ml of complete medium with or without 2 mM catalytically
active, catalytically inactive or random ribozyme, respectively,
was added. After 3 weeks, single cells and colonies were
counted and the ratios between single cells and colonies deter-
mined. Data are expressed as mean ±SEM and compared by
Fisher’s exact test.
RESULTS
The 2'-O-allyl modified anti-Ki-ras hammerhead ribozyme
was designed to cleave the mutant Ki-ras mRNA with a GUU
motif at codon 12, but not wild type Ki-ras mRNA which has
a GGU motif at this position. The catalytically inactive
r i b o z y m eh a st h es a m es e q u e n c ea n dm o d i f i c a t i o n sa st h e
catalytically active ribozyme except for a 2'-O-allyl modification
of the ribonucleotide in position 5. Through this modification
the catalytically inactive ribozyme retains antisense properties.
The random ribozyme as a negative control has the core
sequence of the hammerhead ribozyme, but random sequences
as binding arms.
In vitro cleavage assay
An in vitro cleavage assay was performed to confirm the catalytic
activity of the hammerhead ribozyme and to exclude cleavage
activity of the catalytically inactive and the random ribozyme.
Catalytically active, catalytically inactive and random
ribozymes were incubated with the in vitro transcribed wild
type and mutated target Ki-ras RNA which represented the
coding region from position 1 to 257 of the Ki-ras cDNA. The
hammerhead ribozyme cleaved the mutated, but not wild type
Ki-ras target RNA (Fig. 1). A large proportion of mutated target
RNA (~50%) was still intact after an incubation for 24 h,
indicating a relatively low in vitro cleavage activity of the
hammerhead ribozyme (12). The catalytically inactive ribozyme
and the random ribozyme showed no detectable cleavage
activity (Fig. 1).
Stability of the ribozymes in cell culture
It has been shown that 2'-O-allyl modified hammerhead
ribozymes are resistant to nuclease degradation in cell culture
systems (13). To investigate the stability of our oligoribo-
nucleotides, the catalytically active anti-Ki-ras ribozyme, the
catalytically inactive ribozyme and the random ribozyme were
incubated with or without CFPAC-1 cells, respectively, in
complete cell culture medium (including 10% non-heat
inactivated FCS) for up to 7 days. In each case no degradation
ofthe ribozymeswas observedafter incubationfor up to 3days
(data not shown). At least 60% of the ribozymes were still
intact after an incubation for 7 days. In contrast, unmodified
ribozymes have a half-life of only ~6 s (14).
Ki-ras mRNA analysis
RT–PCR analysis of Ki-ras mRNA was performed to inves-
tigate the effects of the ribozymes on the Ki-ras mRNA level
in CFPAC-1 cells. Two different RT–PCRs were performed,
which generated either a ‘long’ amplicon including the
ribozymehybridizationandcleavagesite,ora ‘short’ amplicon
of the 3'-end of the ‘long’ amplicon which lacks the hybrid-
ization site (Fig. 2A). This RT–PCR design serves as a model
to show specific activity of the ribozymes (Materials and
Methods).
As illustrated in Figure 2B and C, the levels of the Ki-ras
mRNA of both the ‘long’ and the ‘short’amplicon decreased in
cells treated with catalytically active or catalytically inactive
ribozyme in a concentration-dependent manner over a range of
0.05–5 mM. The generation of the ‘long’ amplicon was more
sensitive to inhibition by ribozyme treatment than the ‘short’
amplicon. Complete inhibition of the long Ki-ras mRNA
amplification was observed at 2 mM (catalytically active
ribozyme) and 5 mM (catalytically inactive ribozyme), indi-
cating suppression of both mutant and wild type Ki-ras mRNA
expression. The random ribozyme revealed no inhibition of Ki-ras
mRNA amplification. As further control, actin RT–PCR was
performed andshowed equalamounts of ampliconsinallreactions,
excluding unspecific effects of the ribozymes.
The ratio of wild type andmutatedformofthe Ki-ras mRNA
in CFPAC-1 cells was determined by cloning of the Ki-ras
cDNA products generated from RNA of untreated cells and
cells treated with 1 mM catalytically active, catalytically inactive2740 Nucleic Acids Research, 1999, Vol. 27, No. 13
or random ribozyme, respectively. At this concentration the
‘long’ Ki-ras RT–PCR amplicon can still be detected in the
presence of all ribozymes (Fig. 2B). From each group,
50 clones were sequenced. Sequence analysis of the Ki-ras
clones from untreated CFPAC-1 cells showed that 38% of the
clones represented wild type Ki-ras mRNA, probably due to
hyperdiploidy of the cells (65–75 chromosomes) (10). Moreover,
cells with multiple mutated Ki-ras alleles may have a growth
advantage as compared with cells possessing only one mutated
Ki-ras allele, implying a mutational pressure to gain multiple
copies of the mutated allele. As shown in Table 1, wild type
sequence of the Ki-ras m R N Aw a so b t a i n e di n5 2 ,3 6a n d3 6 %
of cDNA clones derived from cells treated with catalytically
active ribozyme, inactive ribozyme or random ribozyme,
respectively. Thus, the catalytically active ribozyme, but not
the catalytically inactive or random ribozyme, shifted the relation
of wild type and mutant Ki-ras mRNA towards the wild type
mRNA.
Effect of the ribozymes on cell proliferation
When CFPAC-1 cells were incubated with catalytically active
or catalytically inactive ribozyme, cell proliferation was
inhibited in a dose-dependent manner (Fig. 3). At a concentration
of 2 mM the catalytically active ribozyme was ~2-fold more
A
B
Figure 1. In vitro cleavage activity of the catalytically active, catalytically inactive anti-Ki-ras ribozyme and a random ribozyme. Fifty picomoles catalytically
active, catalytically inactive or random ribozyme were mixed with 10 pmol of wild type or mutant target RNA (position 1–257 of Ki-ras mRNA plus 24 nt poly-T
tail). The cleavage was started by adding MgCl2 (10 mM) as described in Materials and Methods. Aliquots at time points 0, 2, 4, 16 and 24 h were mixed with
formamide, heat denatured at 95°C for 10 min and visualized by denaturing 6% polyacrylamide–urea gel electrophoresis and silver staining (A). Cleavage at
position 35 results in a band of 246 (arrow) and 35 ribonucleotides (not visualized on the gel). Bands referring to the cleavage activity of the catalytically active
ribozyme were quantified by laser densitometry (B).Nucleic Acids Research, 1999, Vol. 27, No. 13 2741
potent than the catalytically inactive ribozyme. The dose–
response curves of the catalytically active and catalytically
inactive ribozyme on cell proliferation were shifted to higher
concentrations after incubation for 48 h compared with the
24 h assay (Fig. 3A and B). The random ribozyme in concen-
trations up to 5 mM showed no effects on cell proliferation.
Cationic lipids have been described to facilitate the uptake of
oligonucleotides into cells (15). To investigate if DOTAP
increase the potency of the catalytically active or catalytically
inactive ribozymes, we examined the effect of this cationic
lipid on cell proliferation at the threshold concentration of the
oligoribonucleotides (0.5 mM). At a ratio of 1:1 DOTAP itself
Table 1. Wild type and mutant Ki-ras mRNAs amplified from untreated cells or cells treated with catalytically
active, catalytically inactive or random ribozyme
CFPAC-1 cells were incubated with catalytically active ribozyme (1 mM), catalytically inactive ribozyme (1 mM),
random ribozyme (1 mM) or without oligoribonucleotides for 48 h. Total RNA was extracted from the cells and
reverse transcribed into cDNA. The ‘long’ amplicon of Ki-ras mRNA was PCR amplified and the products were
cloned. For each condition, 50 clones were sequenced.
Wild type Mutant type Wild type/
clones (GGU) clones (GUU) total clones (%)
Untreated control 19 31 38
Catalytically active ribozyme 26 24 52
Catalytically inactive ribozyme 18 32 36
Random ribozyme 18 32 36
Figure 2. Effect of the catalytically active, catalytically inactive ribozyme and random ribozyme on Ki-ras mRNA. CFPAC-1 cells were incubated for 48 h without
and with catalytically active ribozyme (closed circles), catalytically inactive ribozyme (open circles) or random ribozymes (triangles), respectively. Total RNA was
extracted from the cells and reverse transcribed into cDNA as described in Materials and Methods. As illustrated in (A) two different PCRs were performed gener-
ating either a ‘long’ amplicon including the ribozyme hybridization and cleavage site (arrow tip) or a ‘short’ amplicon excluding the ribozyme hybridization site.
‘Long’ and ‘short’ amplicons were separated on agarose gels and bands subsequently analyzed by laser densitometry (B and C). The data shown are representative
for two independent experiments.2742 Nucleic Acids Research, 1999, Vol. 27, No. 13
inhibited cell proliferation by ~20%. Higher DOTAP concen-
trations were toxic to the cells, while the effects of the anti-Ki-ras
ribozymes on cell proliferation were not influenced by the
addition of DOTAP in ratios from 4:1 to 1:1 (data not shown).
Another cationic lipid, Lipofectin, inhibited cell proliferation
completely after 48 h (data not shown). Thus, the use of
DOTAP and Lipofectin did not improve the effectiveness of
the ribozymes in CFPAC-1 cells under the applied experimental
conditions.
Colony formation in soft agar
We next investigated whether inhibition of expression of Ki-ras
oncogene results in a less malignant phenotype of the CFPAC-1
cells. Therefore, we studied the effect of the ribozymes on colony
formation of CFPAC-1 cells in soft agar. A ribozyme concen-
tration of 2 mM was chosen because at this concentration the
‘ l o n g ’a m p l i c o no fK i - ras mRNA could not be amplified from
cells treated with the catalytically active ribozyme (Fig. 2B).
From 1000 cells that had been initially seeded, a total of
500 single cells/colonies were counted after an incubation for
3 weeks. Colony formation was found in 82% of untreated
cells, in 81% of cells treated with the random ribozyme, and in
71 and 46% of cells treated with the catalytically inactive or
catalytically active ribozyme, respectively (P < 0.0001 for
untreated cells versus cells treated with catalytically inactive
and catalytically active ribozyme, respectively; Table 2). Thus,
similar to the effect on Ki-ras expression and cell proliferation,
the catalytically active ribozyme was more potent than the cat-
alytically inactive ribozyme.
DISCUSSION
Hammerhead ribozymes possess catalytic activity in addition
to antisense effects, the latter being defined as hybridization of
the oligoribonucleotide with the target RNA leading to trans-
lation arrest or degradation of the target mRNA through dsRNases
(16). Earlier studies investigating the properties of ribozymes
did not carefully differentiate and quantitate the antisense and
Figure 3. Dose–response curve for the effect of the ribozymes on cell proliferation. After preincubation for 3 days, CFPAC-1 cells were incubated without and with
increasing concentrations of catalytically active (closed circles), catalytically inactive (open circles) and random ribozyme (triangles) for 24 and 48 h, respectively.
Then, proliferation was measured by BrdU incorporation into synthesized DNA as described in Materials and Methods. The data shown are mean ±SEM of fourt o
six independent experiments.
Table 2. Effect of catalytically active, catalytically inactive or random ribozyme on colony formation in soft agar
Untreated cells and cells treated with 2 mM catalytically active, catalytically inactive or random ribozyme
were seeded in duplicate in 24-well plates (1000 cells per well) in 0.33% soft agar, layered on top of a
0.5% soft agar base layer with complete cell culture medium. After the first and the second week, 200 mlo f
complete medium with or without 2 mM catalytically active, catalytically inactive or random ribozyme,
respectively, were added. After 3 weeks the ratio between single cells and colonies was determined.
Results are means ±SEM of three independent experiments.
Single cells Colonies Colonies/
(single cells + colonies) (%)
Untreated control 89 ± 5 411 ± 5 82
Catalytically active ribozyme 269 ± 7 231 ± 7 46
Catalytically inactive ribozyme 147 ± 12 353 ± 12 71
Random ribozyme 97 ± 8 403 ± 8 81Nucleic Acids Research, 1999, Vol. 27, No. 13 2743
catalytic effects (17,18). Therefore, the aims of the present
study were (i) to demonstrate that the anti-Ki-ras hammerhead
ribozyme cleaves the target mRNA in cultured pancreatic car-
cinoma cells and (ii) to quantitate the ratio of antisense and
cleavage activity. The relationship between antisense and
cleavage activity is important with respect to a complete
inhibition of oncogene expression without influencing the
expression of the wild type Ki-ras mRNA. CFPAC-1 cells
express both wild type and mutated Ki-ras mRNAwitha GUU
mutation in codon 12 and are therefore well suited to differen-
tiate between cleavage and antisense activity of a ribozyme
that specifically cleaves mutant Ki-ras mRNA.
Ki-ras mutations in codon 12 are observed in ~90% of
human pancreatic carcinomas. The frequency of yet published
mutations are GAU (47%), GUU (27%), CGU (15%), UGU
(9%), AGU (1%) and GCU (1%) (19). Hammerhead
ribozymes require an NUX motif (N corresponds to any ribo-
nucleotide and X to A, C or U) in the target RNA for catalytic
cleavage activity. Since the first position of codon 13 in Ki-ras
gene contains a guanine, only the GUU mutation in codon 12
can be approached by a hammerhead ribozyme specifically
designed to cleave oncogenic Ki-rasmRNA. Among the different
sequences fulfilling the required NUX cleavage motif for
hammerhead ribozymes GUC appears to be the optimal triplet
(20). In vitro the efficacy of cleavage of the GUC motif is
generally higher compared with the cleavage efficiency of the
GUU motif (5,12,21). Differences in cleavage activity of
ribozymes can also be related to different flanking sequences
and/or different secondary structures of the target RNAs
(17,22). The in vitro catalytic activity of ribozymes, however,
might be different from in vivo experiments in cultured cells
(23). For instance, it has been reported that a ribozyme that
showed a low catalytic activity in vitro effectively degraded its
target RNA in a cell culture system (24). Most, if not all, RNAs
normally exist in vivo as ribonucleoprotein (RNP) complexes
and not as free molecules. Such RNP complexes may inhibit
ribozyme activity by steric hindrance or, alternatively, enhance
activity via annealing and strand-exchange activities. Further-
more, RNA hybridization may require ‘chaperones’ in the
sense of hybrid promoting proteins or RNA helicases, which
can dissolve intramolecular structures in favor of inter-
molecular structures (25).
Thisstudyprovides severallines ofevidencethatthecatalytically
active ribozyme cleaves the target RNA in a cell culture system.
(i) The catalytically active ribozyme, but not the catalytically
inactive or the random ribozyme shifted the relation between
wild type and mutated Ki-ras mRNA towards wild type
mRNA. (ii) The catalytically active ribozyme was ~2-fold
more potent than the catalytically inactive ribozyme to
decrease expression of Ki-ras mRNA and to inhibit cell prolif-
eration and colony formation in soft agar.
The dose–response curves for the effects of the catalytically
active and catalytically inactive anti-Ki-ras ribozymes on cell
proliferation were shifted to higher concentrations after
incubation for 48 h compared with 24 h incubation. It remains
speculative whether this observation is due to an adaptation of
the cells in the presence of the ribozymes (e.g. activation of
alternative signal transductionpathways)ordueto intracellular
degradation of the ribozymes. The latter explanation, however,
appears less likely because (i) the stability of the ribozymes in
cell culture medium with non-heat-inactivated FCS was high
with a half-life of ~7 days and (ii) Ki-ras mRNA was undetectable
after a 48 h incubation with a catalytically active ribozyme at a
concentration of ³2 mM.
In a previous study, a 2'-O-allyl modified ribozyme and a 2'-
O-allyl modified antisense oligoribonucleotide designed to
degrade amelogenin mRNA were injected into the proximity
of the developing mandibular molar teeth in newborn mice and
resulted in a prolonged and specific arrest of amelogenin
synthesis (26). In that study the antisense oligoribonucleotide
was 80% as effective as the hammerhead ribozyme, but its
effect was of shorter duration. A hammerhead ribozyme
designed to degrade mutant Ha-ras mRNA has been shown to
suppress the transformed phenotype of NIH 3T3 cells (27). In
another study, the effects of phosphorothioate-modified anti-
sense oligonucleotides directed against Ki-ras mRNA were
investigated in the human urinary bladder carcinoma cell line
T24 and were found to reduce the level of Ki-ras mRNA as
well as cell proliferation (28). However, phosphorothioate-
modified oligonucleotides are especially prone to cause
unspecific effects by binding to various proteins (29–31).
Although some of these side effects will almost certainly have
clinical value, they make it hard to produce drugs that act
primarily through true antisense mechanisms and complicate
the use of phosphorothioate-modified antisense oligonucleo-
tides as research reagents (23). We have also studied phospho-
rothioate-modified antisense oligonucleotides in CFPAC-1
cells, and could not observe specific effects on cell prolif-
eration (unpublished data).
It is generally anticipated that chemically synthesized anti-
sense oligoribonucleotides act through translation arrest (32).
The data of the present study show that the catalytically active
ribozyme is more effective than the catalytically inactive
ribozyme. However, both anti-Ki-ras ribozymes but not the
random control ribozyme lead to degradation of wild type and
mutatedKi-rasmRNA indicating anindirect RNA degradation
process in addition to translation arrest. As shown by the spe-
cifically designed RT–PCR assay, both the catalytically active
and catalytically inactive ribozyme are more effective in
decreasing the levels of the ‘long’ Ki-ras mRNA compared
with the ‘short’ Ki-ras mRNA. This indicates that the cata-
lytically active and catalytically inactive ribozyme specifically
hybridize at the predicted site, excluding unspecific effects.
Hybridization of the anti-Ki-ras ribozymes at the predicted
site could lead to degradation of both wild type and mutated
Ki-ras mRNA by dsRNases. Recently, Wu et al. investigated
antisense oligoribonucleotides with 2'-O-methyl modifications
targeted to point mutated Ha-ras mRNA and found a dose-
dependent reduction of the Ha-ras mRNA (16). Neither single
strand nucleases nor mammalian or Escherichia coli RNase HI
cleaved the RNA duplex. The dsRNase activity resulted in
cleavage products with 5'-phosphate and 3'-hydroxyl termini.
Wu et al. partially purified the dsRNase activity and found an
enzyme with a molecular weight of 50 000–65 000 Da. Other
enzymes with dsRNase activity have been described and
partially purified (33,34).
The anti-Ki-ras ribozyme used in the present study wasthree
times more effective in reducing colony formation in soft agar
than the catalytically inactive ribozyme. This could be inter-
preted to mean that the catalytically active ribozyme affects
malignancy of CFPAC-1 cells. However,it is also possible that
this reflects an increased growth inhibitory effect of the2744 Nucleic Acids Research, 1999, Vol. 27, No. 13
catalytically active ribozyme compared with the catalytically
inactive ribozyme rather than a loss of malignancy. Colony
formation was not completely blocked, although the ‘long’
amplicon of Ki-ras mRNA was undetectable in the cells
treated with catalytically active ribozyme. Most likely, the
activating Ki-ras mutation is not the only oncogene causing
proliferation and malignant phenotype in CFPAC-1 cells. As
has been shown for other tumor cell lines, additional onco-
genes and mutated tumor suppressor genes contribute to the
malignant phenotype of these cells (35).
Cationic lipids are widely used to facilitate uptake of oligo-
nucleotides into cells. In some (36–38), but not all, systems
(39–41) cationic lipids increase the potency of oligonucleo-
tides. In addition, hammerhead ribozymes may enter cells by
endocytic mechanisms similar to that reported for a variety of
antisense oligonucleotides (42). In the present study, the
specific effects of the ribozymes in the absence of cationic
lipids suggest efficient transport of the oligoribonucleotides
into CFPAC-1 cells. This might be facilitated by the increased
hydrophobicity of 2'-O-allyl modified ribozymes compared
with other modifications.
From the results obtained in vitro and in cell culture, we
cannot predict the biological consequences when wild type Ki-ras
mRNA would be affected in humans by a mutation-specific
therapeutic anti-Ki-ras ribozyme. However, in preclinical
trials, farnesyltransferase inhibitors, which are designed to
inhibit membrane insertion of wild type and mutated Ras
proteins, were well tolerated (43).
In conclusion, the results of the present study show that the
cleavage activity of the Ki-ras directed 2'-O-allyl modified
catalytically active ribozyme strongly increases the ability to
degrade the target RNA as compared with a catalytically
inactive ribozyme possessing only antisense effects. Anti-Ki-ras
hammerheadribozymesmaybeapromisingtoolforthetreatment
of pancreatic carcinomas with an oncogenic GTT mutation in
codon 12 of the Ki-ras gene.
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